Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey.
Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, Noventa S, Rapposelli IG, Garajova I, Tortora G, Rodriquenz MG, Bittoni A, Penzo E, De Lorenzo S, Peretti U, Paratore C, Bernardini I, Mosconi S, Spallanzani A, Macchini M, Tamburini E, Bencardino K, Giommoni E, Scartozzi M, Forti L, Valente MM, Militello AM, Cascinu S, Milella M, Reni M. Orsi G, et al. ESMO Open. 2021 Oct;6(5):100238. doi: 10.1016/j.esmoop.2021.100238. Epub 2021 Aug 13. ESMO Open. 2021. PMID: 34392104 Free PMC article.
Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Spallanzani A, Orsi G, Andrikou K, Gelsomino F, Rimini M, Riggi L, Cascinu S. Spallanzani A, et al. Among authors: orsi g. Expert Rev Anticancer Ther. 2018 Nov;18(11):1069-1076. doi: 10.1080/14737140.2018.1524297. Epub 2018 Sep 21. Expert Rev Anticancer Ther. 2018. PMID: 30220234 Review.
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib.
Marisi G, Petracci E, Raimondi F, Faloppi L, Foschi FG, Lauletta G, Iavarone M, Canale M, Valgiusti M, Neri LM, Ulivi P, Orsi G, Rovesti G, Vukotic R, Conti F, Cucchetti A, Ercolani G, Andrikou K, Cascinu S, Scartozzi M, Casadei-Gardini A. Marisi G, et al. Among authors: orsi g. Cancers (Basel). 2019 Jul 20;11(7):1023. doi: 10.3390/cancers11071023. Cancers (Basel). 2019. PMID: 31330833 Free PMC article.
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort.
Casadei-Gardini A, Solaini L, Riggi L, Molinaro E, Dadduzio V, Rizzato MD, Pellino A, Faloppi L, Marisi G, Ulivi P, Canale M, Orsi G, Rovesti G, Andrikou K, Spallanzani A, Gelsomino F, Foschi FG, Conti F, Cucchetti A, Ercolani G, Biason P, Lonardi S, Cascinu S, Scartozzi M. Casadei-Gardini A, et al. Among authors: orsi g. Gastrointest Tumors. 2019 Oct;6(3-4):71-80. doi: 10.1159/000501593. Epub 2019 Aug 20. Gastrointest Tumors. 2019. PMID: 31768351 Free PMC article.
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience.
Rovesti G, Orsi G, Kalliopi A, Vivaldi C, Marisi G, Faloppi L, Foschi FG, Silvestris N, Pecora I, Aprile G, Molinaro E, Riggi L, Ulivi P, Canale M, Cucchetti A, Tamburini E, Ercolani G, Fornaro L, Andreone P, Zavattari P, Scartozzi M, Cascinu S, Casadei-Gardini A. Rovesti G, et al. Among authors: orsi g. Gastrointest Tumors. 2019 Oct;6(3-4):92-107. doi: 10.1159/000502714. Epub 2019 Sep 12. Gastrointest Tumors. 2019. PMID: 31768353 Free PMC article.
Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis.
Casadei-Gardini A, Vagheggini A, Gelsomino F, Spallanzani A, Ulivi P, Orsi G, Rovesti G, Andrikou K, Tamburini E, Scartozzi M, Cascinu S. Casadei-Gardini A, et al. Among authors: orsi g. Clin Colorectal Cancer. 2020 Jun;19(2):82-90.e9. doi: 10.1016/j.clcc.2019.10.001. Epub 2020 Mar 17. Clin Colorectal Cancer. 2020. PMID: 32192883
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study.
Casadei-Gardini A, Marisi G, Dadduzio V, Gramantieri L, Faloppi L, Ulivi P, Foschi FG, Tamburini E, Vivaldi C, Rizzato MD, Ielasi L, Canale M, Conti F, Rudnas B, Fornaro L, Silvestris N, Silletta M, Cardellino GG, Lonardi S, Fornari F, Orsi G, Rovesti G, Zagonel V, Cascinu S, Scartozzi M. Casadei-Gardini A, et al. Among authors: orsi g. Clin Cancer Res. 2020 Sep 1;26(17):4485-4493. doi: 10.1158/1078-0432.CCR-19-3897. Epub 2020 May 5. Clin Cancer Res. 2020. PMID: 32371540
435 results